Dysregulation of sphingolipid metabolism in liver fibrosis

Abstract

The dysregulation of sphingolipid metabolism emerges as a pivotal factor in the development and progression of liver fibrosis, a condition marked by the overproduction and buildup of extracellular matrix proteins that can lead to liver cirrhosis and failure. Sphingolipids, a diverse class of lipids essential for cellular structure and signaling, are integral to numerous biological functions such as cellular proliferation, morphological differentiation, and programmed cell death. In the context of liver fibrosis, changes in sphingolipid metabolism have been associated with the activation of hepatic stellate cells, the primary cells responsible for fibrogenesis in the liver. These metabolic disruptions lead to an imbalance between profibrotic and antifibrotic sphingolipids, notably sphingosine-1-phosphate and ceramide, contributing to the pathophysiological mechanisms that drive fibrosis. The intricate relationship between sphingolipid metabolism and fibrotic pathways underscores the potential of targeting sphingolipid metabolic enzymes and receptors as therapeutic strategies to mitigate liver fibrosis. The core of this review delves into how disruptions in sphingolipid metabolism contribute to liver fibrosis, exploring biomarkers and potential therapeutic targets. Challenges in research and future directions for comprehensively understanding sphingolipid roles in liver fibrosis are discussed, aiming to open new pathways for therapeutic intervention.

Keywords

Sphingolipids / liver fibrosis / SphK / S1P

References

[1] BatallerR.Liver fibrosis.J Clin Invest2005;115:209-18 PMCID:PMC546435

[2] RoehlenN,BaumertTF.Liver fibrosis: mechanistic concepts and therapeutic perspectives.Cells2020;9:875 PMCID:PMC7226751

[3] GinèsP,AbraldesJG,FabrellasN.Liver cirrhosis.Lancet2021;398:1359-76

[4] NeshatSY,WangY,DoloffJC.Liver disease: induction, progression, immunological mechanisms, and therapeutic interventions.Int J Mol Sci2021;22:6777 PMCID:PMC8267746

[5] LoewithR,WinssingerN.Sphingolipids and membrane targets for therapeutics.Curr Opin Chem Biol2019;50:19-28

[6] CalzadaC,PenhoatA,MichalskiMC.Role of circulating sphingolipids in lipid metabolism: why dietary lipids matter.Front Nutr2022;9:1108098 PMCID:PMC9874159

[7] Rao R, Vaidyanathan N, Rengasamy M, Mammen Oommen A, Somaiya N, Jagannath MR. Sphingolipid metabolic pathway: an overview of major roles played in human diseases.J Lipids2013;2013:178910 PMCID:PMC3747619

[8] QuinvilleBM,RyckmanAE.A comprehensive review: sphingolipid metabolism and implications of disruption in sphingolipid homeostasis.Int J Mol Sci2021;22:5793 PMCID:PMC8198874

[9] XiaoS,LiC,YuQ.The role of sphingosine-1-phosphate in autophagy and related disorders.Cell Death Discov2023;9:380 PMCID:PMC10584985

[10] NojimaH,MurakamiT,KodaK.Critical roles of the sphingolipid metabolic pathway in liver regeneration, hepatocellular carcinoma progression and therapy.Cancers (Basel)2024;16:850 PMCID:PMC10931359

[11] ZhuC,ZhangX,LiX.Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.Int J Biol Sci2023;19:311-30 PMCID:PMC9760443

[12] IshayY,KhouryT.The role of the sphingolipid pathway in liver fibrosis: an emerging new potential target for novel therapies.Am J Physiol Cell Physiol2020;318:C1055-64

[13] JacksonKG,ZhouH.Bile acids and sphingolipids in non-alcoholic fatty liver disease.Chin Med J (Engl)2022;135:1163-71 PMCID:PMC9337250

[14] LuoN,WeiY,DongR.Hepatic stellate cell: a double-edged sword in the liver.Physiol Res2021;70:821-9 PMCID:PMC8815467

[15] SimonJ,Ala-IbaniboL,DelgadoTC.Sphingolipids in non-alcoholic fatty liver disease and hepatocellular carcinoma: ceramide turnover.Int J Mol Sci2019;21:40 PMCID:PMC6982102

[16] ChangH,LiuSM.Identification of key metabolic changes during liver fibrosis progression in rats using a urine and serum metabolomics approach.Sci Rep2017;7:11433 PMCID:PMC5595818

[17] HollandWL.Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.Endocr Rev2008;29:381-402 PMCID:PMC2528849

[18] ParkKH,ZhangJ.3-ketodihydrosphingosine reductase mutation induces steatosis and hepatic injury in zebrafish.Sci Rep2019;9:1138 PMCID:PMC6361991

[19] MullenTD,ObeidLM.Ceramide synthases at the centre of sphingolipid metabolism and biology.Biochem J2012;441:789-802 PMCID:PMC3689921

[20] LevyM.Mammalian ceramide synthases.IUBMB Life2010;62:347-56 PMCID:PMC2858252

[21] BartkeN.Bioactive sphingolipids: metabolism and function.J Lipid Res2009;50 Suppl:S91-6 PMCID:PMC2674734

[22] RezaS,SuchańskiJ.Glucosylceramide and galactosylceramide, small glycosphingolipids with significant impact on health and disease.Glycobiology2021;31:1416-34 PMCID:PMC8684486

[23] LeeM,BaeYS.Functional roles of sphingolipids in immunity and their implication in disease.Exp Mol Med2023;55:1110-30 PMCID:PMC10318102

[24] YangF.The nutritional functions of dietary sphingomyelin and its applications in food.Front Nutr2022;9:1002574 PMCID:PMC9626766

[25] JamjoumR,IsslenyB.Mysterious sphingolipids: metabolic interrelationships at the center of pathophysiology.Front Physiol2023;14:1229108 PMCID:PMC10791800

[26] HlaT.Physiological and pathological actions of sphingosine 1-phosphate.Semin Cell Dev Biol2004;15:513-20

[27] SpiegelS.Sphingosine-1-phosphate: an enigmatic signalling lipid.Nat Rev Mol Cell Biol2003;4:397-407

[28] GrassiS,PrioniS.Sphingosine 1-phosphate receptors and metabolic enzymes as druggable targets for brain diseases.Front Pharmacol2019;10:807 PMCID:PMC6689979

[29] YuXD.Ceramide de novo synthesis in non-alcoholic fatty liver disease: pathogenic mechanisms and therapeutic perspectives.Biochem Pharmacol2022;202:115157

[30] ThomasS,HochA,Diray-ArceJ.The implication of sphingolipids in viral infections.Int J Mol Sci2023;24:17303 PMCID:PMC10743733

[31] BouscaryA,RenéF.Sphingolipids metabolism alteration in the central nervous system: amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.Semin Cell Dev Biol2021;112:82-91

[32] JannehAH.Targeting sphingolipid metabolism as a therapeutic strategy in cancer treatment.Cancers (Basel)2022;14:2183 PMCID:PMC9104917

[33] Gomez-LarrauriA,Dominguez-HerreraA,TruebaM.Role of bioactive sphingolipids in physiology and pathology.Essays Biochem2020;64:579-89

[34] AjiG,NgML.Regulation of hepatic insulin signaling and glucose homeostasis by sphingosine kinase 2.Proc Natl Acad Sci U S A2020;117:24434-42 PMCID:PMC7533871

[35] WiggerD,Schneider-SchauliesS.Sphingosine 1-phosphate metabolism and insulin signaling.Cell Signal2021;82:109959

[36] PiccoliM,GhiroldiA.Sphingolipids and atherosclerosis: the dual role of ceramide and sphingosine-1-phosphate.Antioxidants (Basel)2023;12:143 PMCID:PMC9855164

[37] ArosioB,DavinelliS.Sex differences in cardiovascular diseases: a matter of estrogens, ceramides, and sphingosine 1-phosphate.Int J Mol Sci2022;23:4009 PMCID:PMC8999971

[38] PeschelG,GrimmJ.Gender-specific differences in serum sphingomyelin species in patients with hepatitis c virus infection-sphingomyelin species are related to the model of end-stage liver disease (MELD) score in male patients.Int J Mol Sci2023;24:8402 PMCID:PMC10179471

[39] KisselevaT.Molecular and cellular mechanisms of liver fibrosis and its regression.Nat Rev Gastroenterol Hepatol2021;18:151-66

[40] HeyensLJM,KoekGH,FrancqueS.Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment.Front Med (Lausanne)2021;8:615978 PMCID:PMC8079659

[41] KammDR.Hepatic stellate cells in physiology and pathology.J Physiol2022;600:1825-37 PMCID:PMC9012702

[42] GarbuzenkoDV.Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis.World J Clin Cases2022;10:3662-76 PMCID:PMC9100727

[43] GandhiCR.Oxidative stress and hepatic stellate cells: a paradoxical relationship.Trends Cell Mol Biol2012;7:1-10 PMCID:PMC5051570

[44] KhomichO,BartoschB.Metabolic hallmarks of hepatic stellate cells in liver fibrosis.Cells2019;9:24 PMCID:PMC7016711

[45] WangZ,JinN,ZhangW.Macrophage in liver fibrosis: identities and mechanisms.Int Immunopharmacol2023;120:110357

[46] Nguyen-LefebvreAT.Kupffer cell metabolism and function.J Enzymol Metab2015;1:101 PMCID:PMC4771376

[47] QianJ,WangG,CaoX.Mechanism of TGF-β1 inhibiting kupffer cell immune responses in cholestatic cirrhosis.Exp Ther Med2020;20:1541-9 PMCID:PMC7388376

[48] GlaserSS,MillerT,AlpiniG.Cholangiocyte proliferation and liver fibrosis.Expert Rev Mol Med2009;11:e7 PMCID:PMC2675635

[49] ParkSM.The crucial role of cholangiocytes in cholangiopathies.Gut Liver2012;6:295-304 PMCID:PMC3404165

[50] CaiX,GuillotA.Cholangiokines: undervalued modulators in the hepatic microenvironment.Front Immunol2023;14:1192840 PMCID:PMC10229055

[51] PhamL,BaiocchiL.Mast cells in liver disease progression: an update on current studies and implications.Hepatology2022;75:213-8 PMCID:PMC9276201

[52] CanbayA,GoresGJ.Apoptosis: the nexus of liver injury and fibrosis.Hepatology2004;39:273-8

[53] KimHY,EguileorA.The origin and fate of liver myofibroblasts.Cell Mol Gastroenterol Hepatol2024;17:93-106 PMCID:PMC10665929

[54] XuJ.Bone marrow-derived fibrocytes contribute to liver fibrosis.Exp Biol Med (Maywood)2015;240:691-700 PMCID:PMC4866973

[55] LafozE,AntonA,Hernández-GeaV.The endothelium as a driver of liver fibrosis and regeneration.Cells2020;9:929 PMCID:PMC7226820

[56] TangJ,FengQ,WangH.The roles of neutrophils in the pathogenesis of liver diseases.Front Immunol2021;12:625472 PMCID:PMC7982672

[57] RahmanAH.Dendritic cells and liver fibrosis.Biochim Biophys Acta2013;1832:998-1004 PMCID:PMC3641166

[58] FrangogiannisN.Transforming growth factor-β in tissue fibrosis.J Exp Med2020;217:e20190103 PMCID:PMC7062524

[59] SunY,XieJ.Aspirin attenuates liver fibrosis by suppressing TGF‑β1/Smad signaling.Mol Med Rep2022;25:181 PMCID:PMC8972277

[60] ZhaoM,WangM.Targeting fibrosis, mechanisms and cilinical trials.Signal Transduct Target Ther2022;7:206 PMCID:PMC9247101

[61] YingHZ,ZhangWY.PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (review).Mol Med Rep2017;16:7879-89 PMCID:PMC5779870

[62] LiuJ,LuoF.The role of JAK/STAT pathway in fibrotic diseases: molecular and cellular mechanisms.Biomolecules2023;13:119 PMCID:PMC9855819

[63] El-AshmawyNE,FakherHE.The role of WNT/β-catenin signaling pathway and glutamine metabolism in the pathogenesis of CCl(4)-induced liver fibrosis: repositioning of niclosamide and concerns about lithium.Cytokine2020;136:155250

[64] DusparaK,PejicJI.Targeting the Wnt signaling pathway in liver fibrosis for drug options: an update.J Clin Transl Hepatol2021;9:960-71 PMCID:PMC8666372

[65] ShenX,LiH.The injury-related activation of hedgehog signaling pathway modulates the repair-associated inflammation in liver fibrosis.Front Immunol2017;8:1450 PMCID:PMC5681491

[66] SalgadoAlvarez GA,GarciaMora U.Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease.World J Hepatol2022;14:1633-42 PMCID:PMC9453468

[67] SatoM,UranbilegB.Sphingosine kinase-1, S1P transporter spinster homolog 2 and S1P2 mRNA expressions are increased in liver with advanced fibrosis in human.Sci Rep2016;6:32119 PMCID:PMC4999825

[68] OsawaY,NakashimaK.Sphingosine-1-phosphate promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis.PLoS One2024;19:e0303296 PMCID:PMC11098361

[69] DingBS,SunY.HDL activation of endothelial sphingosine-1-phosphate receptor-1 (S1P(1)) promotes regeneration and suppresses fibrosis in the liver.JCI Insight2016;1:e87058 PMCID:PMC5161208

[70] LiuX,LiC,YouH.Essential roles of sphingosine 1-phosphate receptor types 1 and 3 in human hepatic stellate cells motility and activation.J Cell Physiol2011;226:2370-7

[71] YangL,LiuX.Bone marrow-derived mesenchymal stem cells differentiate to hepatic myofibroblasts by transforming growth factor-β1 via sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis.Am J Pathol2012;181:85-97

[72] HouL,ChangN.Macrophage sphingosine 1-phosphate receptor 2 blockade attenuates liver inflammation and fibrogenesis triggered by NLRP3 inflammasome.Front Immunol2020;11:1149 PMCID:PMC7333785

[73] KingA,KavanaghD.Sphingosine-1-phosphate prevents egress of hematopoietic stem cells from liver to reduce fibrosis.Gastroenterology2017;153:233-248.e16 PMCID:PMC5511862

[74] NagahashiM,LiuR.Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression.Hepatology2015;61:1216-26 PMCID:PMC4376566

[75] XiaoY,LiX.Long noncoding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia.Hepatology2019;70:1658-73 PMCID:PMC6819224

[76] IslamD,TalebMAB.A novel model to study mechanisms of cholestasis in human cholangiocytes reveals a role for the SIPR2 pathway.Hepatol Commun2024;8 PMCID:PMC10898671

[77] YangJ,LiangZ,SunL.Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions.Clin Mol Hepatol2023;29:465-81 PMCID:PMC10121313

[78] IkedaH,IshiiI.Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2.J Lipid Res2009;50:556-64 PMCID:PMC2638109

[79] BrunatiAM,CarraroA.Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures.Biochim Biophys Acta2008;1783:347-59

[80] KawaiH,MatsudaM.Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.Hepatology2022;76:112-25

[81] YangL,YangL.Sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis is involved in liver fibrosis-associated angiogenesis.J Hepatol2013;59:114-23

[82] LiaoCY,GaoY,RevzinA.Hepatocyte-derived lipotoxic extracellular vesicle sphingosine 1-phosphate induces macrophage chemotaxis.Front Immunol2018;9:2980 PMCID:PMC6305739

[83] Fadel F, Fayyaz S, Japtok L, Kleuser B. Involvement of sphingosine 1-phosphate in palmitate-induced non-alcoholic fatty liver disease.Cell Physiol Biochem2016;40:1637-45

[84] MontefuscoD,MaczisMA.Sphingosine kinase 1 mediates sexual dimorphism in fibrosis in a mouse model of NASH.Mol Metab2022;62:101523 PMCID:PMC9194589

[85] LiaoY,DuanY.Liver sinusoidal endothelial S1pr2 regulates experimental liver fibrosis through YAP/TGF-β signaling pathway.FASEB J2023;37:e22905

[86] NojimaH,SchusterRM.Hepatocyte exosomes mediate liver repair and regeneration via sphingosine-1-phosphate.J Hepatol2016;64:60-8 PMCID:PMC4843792

[87] SugimotoM,WakabayasiM.Sphingomyelin synthase 2 loss suppresses steatosis but exacerbates fibrosis in the liver of mice fed with choline-deficient, L-amino acid-defined, high-fat diet.Biochem Biophys Res Commun2020;533:1269-75

[88] LeeAY,KimJE.Dihydroceramide is a key metabolite that regulates autophagy and promotes fibrosis in hepatic steatosis model.Biochem Biophys Res Commun2017;494:460-9

[89] ThieleM,TroštK.MicrobLiver ConsortiumGALAXY ConsortiumSphingolipids are depleted in alcohol-related liver fibrosis.Gastroenterology2023;164:1248-60

[90] BawejaS,NegiP.Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.J Hepatol2023;79:167-80

[91] McGinleyMP.Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.Lancet2021;398:1184-94

[92] SandbornWJ,Peyrin-BirouletL.Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.Lancet2023;401:1159-71

[93] MauerAS,MaiersJL,MalhiH.Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis.Am J Physiol Gastrointest Liver Physiol2017;312:G300-13 PMCID:PMC5401989

[94] WangY,YangJ.The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.Hepatology2017;65:2005-18 PMCID:PMC5444993

[95] YangL,TianL.Sphingosine 1-phosphate receptor 2 and 3 mediate bone marrow-derived monocyte/macrophage motility in cholestatic liver injury in mice.Sci Rep2015;5:13423 PMCID:PMC4555045

[96] IkedaH,YanaseM.Sphingosine 1-phosphate enhances portal pressure in isolated perfused liver via S1P2 with Rho activation.Biochem Biophys Res Commun2004;320:754-9

[97] CaoH,ZengZ.Reversal of cholestatic liver disease by the inhibition of sphingosine 1-phosphate receptor 2 signaling.PeerJ2024;12:e16744 PMCID:PMC10798156

[98] HongCH,KimJH.Sphingosine 1-phosphate receptor 4 promotes nonalcoholic steatohepatitis by activating NLRP3 inflammasome.Cell Mol Gastroenterol Hepatol2022;13:925-47 PMCID:PMC8810559

[99] González-FernándezB,CrespoI.Inhibition of the SphK1/S1P signaling pathway by melatonin in mice with liver fibrosis and human hepatic stellate cells.Biofactors2017;43:272-82

[100] HadaN,KenichiK,HoribaN.Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH).Pharmacol Res Perspect2023;11:e01094 PMCID:PMC10197225

[101] MarroneA,AlfieriG.Epstein barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment.Infez Med2014;22:331-6

[102] LiM,ChenF.Co-stimulation of LPAR₁ and S1PR_1/3 increases the transplantation efficacy of human mesenchymal stem cells in drug-induced and alcoholic liver diseases.Stem Cell Res Ther2018;9:161 PMCID:PMC6000942

[103] XuW,ZhangF,ZhengS.Dihydroartemisinin restricts hepatic stellate cell contraction via an FXR-S1PR2-dependent mechanism.IUBMB Life2016;68:376-87

[104] RomanoA,DelCoco L.Chronic oleoylethanolamide treatment decreases hepatic triacylglycerol level in rat liver by a PPARγ/SREBP-mediated suppression of fatty acid and triacylglycerol synthesis.Nutrients2021;13:394 PMCID:PMC7910994

[105] ChenL,ChenJ.Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells.Oncotarget2015;6:42530-40 PMCID:PMC4767450

[106] WuHC,WangW.Potential hepatic lipid markers associated with nonalcoholic steatohepatitis and fibrosis in morbid obesity patients.J Clin Med2023;12:3730 PMCID:PMC10253728

[107] LiJF,ZhengSJ.Plasma sphingolipids: potential biomarkers for severe hepatic fibrosis in chronic hepatitis C.Mol Med Rep2015;12:323-30